Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: BAD BILLY who wrote (2789)	1/18/1998 6:40:00 PM
From: Afaq Sarwar	Respond to of 3906

BAD BILLY, If they can find a suiter willing to pay a fair price, that might be a good outcome. I would like to think that the buyout will not occur at the current valuation (around $50 mil.). If they do not have a patent that does not infringe on claim no. 6 of Gene Voss's patent (licenced by VVUS), no one would be interested in buying them out. But if their patent is as good as they seem to think, then $50 mil. would be too low a valuation for their drug and the delivery system. The lower end of the fair value may be around $250 mil. in my opinion. If they sell at that or higher valuation, I would consider that they deserve their 18 mil/ shares. Afaq Sarwar